



**ASX RELEASE**  
**17 September 2013**

**Sydney, Australia and Bedminster, New Jersey** – QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) advises pursuant to ASX Listing Rule 3.13.1, that it will hold its 2013 Annual General Meeting on Wednesday, 13 November 2013 commencing at 10.00am Australian Eastern Daylight Time (AEDT), at DibbsBarker Lawyers, Level 8, 123 Pitt Street, Sydney, Australia.

A formal Notice of the 2013 Annual General Meeting will be sent to the ordinary shareholders of the Company in due course.

###

**Media Contact Information:**

Lisa Fels  
Brightline Strategies  
Tel: +1 703 739 2424 x110  
Email: [lfels@brightlinestrategies.com](mailto:lfels@brightlinestrategies.com)

Kyahn Williamson  
Buchan Consulting  
Tel: +61 401 018 828  
Email: [kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)

**About QRxPharma**

QRxPharma Limited is an Australian based, commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management. The Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company's lead product candidate, immediate release MOXDUO<sup>®</sup> for the treatment of acute pain, is presently under review at the US Food and Drug Administration. QRxPharma entered into strategic collaborations with Actavis Inc. in December 2011, Paladin Labs Inc. in October 2012 and Aspen in September 2013 for the commercialisation of immediate release MOXDUO in the US, Canadian and Australian / New Zealand / Oceania, acute pain markets respectively. In July 2013, QRxPharma announced a collaboration agreement with Aesica Formulation Development Limited, for the world-wide promotion of QRxPharma's proprietary Stealth Beadlets<sup>®</sup> abuse deterrence technology. The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of MOXDUO. For more information, visit [www.qrxpharma.com](http://www.qrxpharma.com).

**Forward Looking Statements**

This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.